Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis.

Capitini CM, Nasholm NM, Duncan BB, Guimond M, Fry TJ.

J Immunol. 2013 Feb 1;190(3):1351-9. doi: 10.4049/jimmunol.1200391. Epub 2012 Dec 28.

3.

Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.

Pyzer AR, Avigan DE, Rosenblatt J.

Hum Vaccin Immunother. 2014;10(11):3125-31. doi: 10.4161/21645515.2014.982993. Review.

4.

Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.

Hailemichael Y, Overwijk WW.

Int J Biochem Cell Biol. 2014 Aug;53:46-50. doi: 10.1016/j.biocel.2014.04.019. Epub 2014 May 2. Review.

5.

Cellular and vaccine immunotherapy for multiple myeloma.

Garfall AL, Stadtmauer EA.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):521-527. Review.

PMID:
27913524
6.

Potential for immunotherapy in soft tissue sarcoma.

Tseng WW, Somaiah N, Engleman EG.

Hum Vaccin Immunother. 2014;10(11):3117-24. doi: 10.4161/21645515.2014.983003. Review.

7.

T Cell Vaccinology: Beyond the Reflection of Infectious Responses.

Pennock ND, Kedl JD, Kedl RM.

Trends Immunol. 2016 Mar;37(3):170-80. doi: 10.1016/j.it.2016.01.001. Epub 2016 Jan 30. Review.

8.

Antigen-Specific Priming is Dispensable in Depletion of Apoptosis-Sensitive T Cells for GvHD Prophylaxis.

Yarkoni S, Stein J, Yaniv I, Askenasy N.

Front Immunol. 2014 May 19;5:215. doi: 10.3389/fimmu.2014.00215. eCollection 2014. Review.

9.

The role of CD8 T lymphocytes in rickettsial infections.

Walker DH, Dumler JS.

Semin Immunopathol. 2015 May;37(3):289-99. doi: 10.1007/s00281-015-0480-x. Epub 2015 Apr 1. Review.

10.

Sex-specific immune modulation of primary hypertension.

Sandberg K, Ji H, Hay M.

Cell Immunol. 2015 Apr;294(2):95-101. doi: 10.1016/j.cellimm.2014.12.001. Epub 2014 Dec 8. Review.

11.

Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine.

Galaine J, Borg C, Godet Y, Adotévi O.

Vaccines (Basel). 2015 Jun 30;3(3):490-502. doi: 10.3390/vaccines3030490. Review.

12.

T-cell-mediated immunity and the role of TRAIL in sepsis-induced immunosuppression.

Condotta SA, Cabrera-Perez J, Badovinac VP, Griffith TS.

Crit Rev Immunol. 2013;33(1):23-40. Review.

13.

Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.

DuPage M, Bluestone JA.

Nat Rev Immunol. 2016 Mar;16(3):149-63. doi: 10.1038/nri.2015.18. Epub 2016 Feb 15. Review.

14.

On the Role of Dendritic Cells Versus Other Cells in Inducing Protective CD8+ T Cell Responses.

Zinkernagel RM.

Front Immunol. 2014 Feb 10;5:30. doi: 10.3389/fimmu.2014.00030. eCollection 2014. Review. No abstract available.

Supplemental Content

Support Center